Lessons for molecular diagnostics in oncology from the Cancer Research UK Stratified Medicine Programme

Expert Review of Molecular Diagnostics

Volumn 15, Issue 3, 2015, Pages 287-289

  Lindsay, Colin R ^a   Shaw, Emily ^a   Walker, Ian ^a   Johnson, Peter Wm ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

cancer; genomics; mutations; sequencing; stratified medicine

Indexed keywords

CANCER RESEARCH; CLINICAL TRIAL (TOPIC); EVIDENCE BASED MEDICINE; FUNDING; HEALTH EDUCATION; HUMAN; INFORMATION PROCESSING; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR DIAGNOSTICS; MOLECULAR PATHOLOGY; NATIONAL HEALTH SERVICE; ONCOLOGY; REVIEW; UNITED KINGDOM; GENETIC SCREENING; GENETICS; GENOMICS; NEOPLASMS; PROCEDURES; RESEARCH; STANDARDS;

TUMOR MARKER;

BIOMARKERS, TUMOR; GENETIC TESTING; GENOMICS; GREAT BRITAIN; HUMANS; NEOPLASMS; PATHOLOGY, MOLECULAR; RESEARCH;

EID: 84923364170     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.2015.992417     Document Type: Review

References (10)

1. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417(6892):949-54
2. Flaherty KT, Puzanov I, Kim KB, et al. 'Inhibition of mutated, activated BRAF in metastatic melanoma.' N Engl J Med 2010; 363(9):809-19
3. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344(14):1031-7
4. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009;361(2):123-34
5. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13(3): 239-46
6. Janne PA, Ramalingam SS, Chih-Hsin Yang J, et al. Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients (pts) with EGFR inhibitor-resistant non-small cell lung cancer (NSCLC). J Clin Oncol 2014; 32(5 Suppl):abstr 8009
7. Sequist LV, Soria JC, Gadgeel SM, et al. First-in-human evaluation of CO-1686, an irreversible, highly selective tyrosine kinase inhibitor of mutations of EGFR (activating and T790M). J Clin Oncol 2014; 32(5 Suppl):abstr 8010
8. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366: 883-92
9. Nowak F, Soria JC, Calvo F. Tumour molecular profiling for deciding therapy-the French initiative. Nat Rev Clin Oncol 2012;9(8):479-86
10. Cooper M, Poole K, Cameron DA, et al. Five-fold increase in recruitment of cancer patients to National Institute for Health Research cancer research network portfolio studies between 2001 and 2011. J Clin Oncol 2012;30(15 Suppl):abstr 6091